 |
 |
 |
 |
 |
 |
 |
|
 |
 |
Press ReleasesGenstruct Presents Outcomes of Diabetes Therapeutics Research at American Diabetes Association 69th Scientific Sessions ConferenceDiabetes Research Conducted with Top Pharmaceutical Market LeaderNew Orleans, La. and Cambridge, Mass. — June 1, 2009 — ( American Diabetes Association 69th Scientific Sessions Conference) Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics, molecular diagnostics and patient-specific therapies, today announced that the outcomes of its most recent diabetes research with one of its top pharmaceutical partners will be presented at the American Diabetes Association’s 69th Scientific Sessions Conference being held in New Orleans, La., June 5-9, 2009. Michael Macoritto, Ph.D., project lead/scientist II at Genstruct will be available to answer questions related to the poster titled, “Comparative Transcriptional Network Modeling of Three PPARα/γ co-agonist Treatments Reveals Unique Metabolic Signatures Despite Similar Core PPAR Signaling” on June 8 from 12:00 – 2:00 p.m. The poster will focus on how Genstruct and its partner investigated the molecular mechanistic effects characterizing and differentiating aleglitazar, a balanced PPAR-α/PPAR-γ agonist, from two other dual PPARα/γ treatments, tesaglitazar and the combination of pioglitazone + fenofibric acid, in human hepatocytes. They used Genstruct’s Causal Network™ modeling platform to identify statistically upstream biological causes to explain the observed data more completely than traditional heat maps. “We’ve used our Causal Network Modeling platform on numerous diabetes research projects,” said Dr. Macoritto. “By leveraging our modeling approach on this project, we were able to help our pharmaceutical partner determine that aleglitazar may have a differential impact on the heart health of diabetic patients compared to other similar therapeutics, particularly in the areas of cholesterol metabolism and cell stress.” About Genstruct Founded in 2002, Genstruct is a systems biology company focused on elucidating the complexity of biology for the development of safe and effective therapeutics and molecular diagnostics. By developing Causal Network™ models for complex biological systems, Genstruct develops a deep molecular understanding of diseases and drug action, and designs mechanistic biomarkers and molecular diagnostics to facilitate drug development and personalized medicine. Genstruct’s Consulting Services division engages in short-, mid- and long-term partnerships with top tier pharmaceutical and life sciences companies, to develop new therapeutics and mechanistic biomarkers in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. Genstruct was awarded the Bio-IT World 2008 Best Practices Award in the Drug Discovery & Development category for its joint collaboration with Sirtris Pharmaceuticals (a GSK company). Genstruct is a privately held company based in Cambridge, Mass. For more information, please visit www.genstruct.com. Contact: Karen Higgins A & E Communications for Genstruct (610) 831-5723 khiggins@aandecomm.com Return to Press Releases |
 |
|
 |
| One Alewife Center | Cambridge, MA 02140 | (617) 547-5421 | sitemap |